Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity
Highlight
– The Metformin Active Surveillance Trial (MAST), a multicenter, randomized, double‑blind, placebo‑controlled phase III trial, found no reduction in time to progression for men with low‑risk prostate cancer assigned to metformin versus placebo over 36 months (HR 1.09; 95% CI 0.79–1.52; P = .59).
– Negative biopsy rates at 36 months were numerically higher with metformin (41.0% vs 31.1%) but did not reach statistical significance (P = .181).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.